The role of FLT3 in haematopoietic malignancies

被引:657
作者
Stirewalt, DL [1 ]
Radich, JP
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] Univ Washington, Div Oncol, Seattle, WA 98109 USA
关键词
D O I
10.1038/nrc1169
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Normal haematopoietic cells use complex systems to control proliferation, differentiation and cell death. The control of proliferation is, in part, accomplished through the ligand-induced stimulation of receptor tyrosine kinases, which signal to downstream effectors through the RAS pathway. Recently, mutations in the FMS-like tyrosine kinase 3 (FLT3) gene, which encodes a receptor tyrosine kinase, have been found to be the most common genetic lesion in acute myeloid leukaemia (AML), occurring in similar to25% of cases. Exploring the mechanism by which these FLT3 mutations cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.
引用
收藏
页码:650 / U1
页数:17
相关论文
共 129 条
  • [1] Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia
    Abu-Duhier, FM
    Goodeve, AC
    Wilson, GA
    Care, RS
    Peake, IR
    Reilly, JT
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 983 - 988
  • [2] Genomic structure of human FLT3:: Implications for mutational analysis
    Abu-Duhier, FM
    Goodeve, AC
    Wilson, GA
    Care, RS
    Peake, IR
    Reilly, JT
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (04) : 1076 - 1077
  • [3] FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group
    Abu-Duhier, FM
    Goodeve, AC
    Wilson, GA
    Gari, MA
    Peake, IR
    Rees, DC
    Vandenberghe, EA
    Winship, PR
    Reilly, JT
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (01) : 190 - 195
  • [4] GENOMIC STRUCTURE OF THE DOWNSTREAM PART OF THE HUMAN FLT3 GENE - EXON/INTRON STRUCTURE CONSERVATION AMONG GENES ENCODING RECEPTOR TYROSINE KINASES (RTK) OF SUBCLASS-III
    AGNES, F
    SHAMOON, B
    DINA, C
    ROSNET, O
    BIRNBAUM, D
    GALIBERT, F
    [J]. GENE, 1994, 145 (02) : 283 - 288
  • [5] Alsabeh R, 1997, AM J CLIN PATHOL, V107, P430
  • [6] Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
    Armstrong, SA
    Kung, AL
    Mabon, ME
    Silverman, LB
    Stam, RW
    Den Boer, ML
    Pieters, R
    Kersey, JH
    Sallan, SE
    Fletcher, JA
    Golub, TR
    Griffin, JD
    Korsmeyer, SJ
    [J]. CANCER CELL, 2003, 3 (02) : 173 - 183
  • [7] MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
    Armstrong, SA
    Staunton, JE
    Silverman, LB
    Pieters, R
    de Boer, ML
    Minden, MD
    Sallan, SE
    Lander, ES
    Golub, TR
    Korsmeyer, SJ
    [J]. NATURE GENETICS, 2002, 30 (01) : 41 - 47
  • [8] Ashihara E, 1998, EUR J HAEMATOL, V60, P86
  • [9] C-kit mutations in core binding factor leukemias
    Beghini, A
    Peterlongo, P
    Ripamonti, CB
    Larizza, L
    Cairoli, R
    Morra, E
    Mecucci, C
    [J]. BLOOD, 2000, 95 (02) : 726 - 727
  • [10] BRASEL K, 1995, LEUKEMIA, V9, P1212